Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: A phase ii study

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 3487-3494

  Zustovich, Fable ^a   Landi, Lorenza ^b   Lombardi, Giuseppe ^b   Porta, Camillo ^c   Galli, Luca ^d   Fontana, Andrea ^d   Amoroso, Domenico ^e   Galli, Costanza ^f   Andreuccetti, Michele ^b   Falcone, Alfredo ^d   Zagonel, Vittorina ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY HOSPITAL OF PISA   (Italy)

^e Ospedale Versilia   (Italy)

^f Azienda USL 6   (Italy)

Author keywords

Chemotherapy; Glioblastoma; Relapse; Sorafenib; Temozolomide

Indexed keywords

SORAFENIB; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; FATIGUE; FEMALE; GLIOBLASTOMA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPERTHYROIDISM; INFECTION; MALE; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

CHEMOTHERAPY; GLIOBLASTOMA; RELAPSE; SORAFENIB; TEMOZOLOMIDE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DACARBAZINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; RECURRENCE; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84883261716     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. James CD, Louis DN and Cavenee WK: Molecular biology of the central nervous system. In: Cancer: Principles and Practice of Oncology. De Vita VT Jr., Hellman S, Rosenberg SA. Philadelphia, PA: Lippincott Williams & Wilkins 1967, 2008.
2. Ohgaki H: Epidemiology of brain tumors. Methods Mol Biol 472: 323-342, 2009.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
4. Frenay M, Giroux B, Khoury S, Derlon JM and Namer M: Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur J Cancer 27: 852-856, 1991.
5. Rodriguez LA, Prados M, Silver P and Levin VA: Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 64: 2420-2423, 1989.
6. Bertolone SJ, Baum ES, Krivit W and Hammond GD. A phase II study of cisplatin therapy in recurrent childhood brain tumors: a report from the Children's Cancer Study Group. J Neurooncol 7: 5-11, 1989.
7. Yung WK, Mechtler L and Gleason MJ: Intravenous carboplatin for recurrent malignant gliomas: A phase II study. J Clin Oncol 9: 860-864, 1991.
8. Chamberlain MC: Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol 56: 183-188, 2002
9. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL and Miller LL: Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17: 1516-1525, 1999.
10. Kappelle AC, Postma TJ, Taphoorn MJ, Groeneveld GJ, van den Bent MJ, van Groeningen CJ, Zonnenberg BA, Sneeuw KC and Heimans JJ: PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 56: 118-120, 2001.
11. Franceschi E, Omuro AM and Lassman AB: Salvage temozolomide for prior temozolomide responders. Cancer 104: 2473-2476, 2005.
12. Kesari S, Ramakrishna N, Sauvageot C, Stiles CD and Wen PY: Target molecular therapy of malignant gliomas. Curr Oncol Rep 8: 58-70, 2006.
13. Reardon D and Wen P: Therapeutic advances in the treatment of glioblastoma: Rationale and potential role of target agents. Oncologist 11: 152-164, 2006.
14. Collova E, Sebastiani F, De Matteis E, Generali D, Aurilio G, Boccardo F, Crispino S and Cruciani G: Use of metronomic chemotherapy in oncology: results from a national Italian survey. Tumori 97: 454-458, 2011.
15. Kurzen H, Schmitt S, Naher H and Mohler T: Inhibition of angiogenesis by non toxic doses of temozolomide. Anticancer Drugs 14: 515-522, 2003.
16. Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P and Pouliot JF: Phase II trial of continuous doseintense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28: 2051-2057, 2010.
17. Kong DS, Lee JI, Kim WS, Son MJ, Lim do H, Kim ST, Park K, Kim JH, Eoh W and Nam DH: A pilot study of metronomic temozolomide treatment in patients with recurrent temozolo-mide-refractory glioblastoma. Oncol Rep 16: 1117-1121 2006.
18. Kong DS, Lee JI, Kim JH, Kim ST, Kim WS, Suh YL, Dong SM and Nam DH: Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol 12: 289-296 2010.
19. Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF and Mellinghoff I: Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol 15: 242-250, 2013.
20. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME and Seeber S: Phase I clinical and pharmacokinetic study of the novel RAF kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23: 965-972, 2005.
21. Hainsworth JD, Ervin T, Friedman E, Priego V, Murphy PB, Clark BL and Lamar RE: Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 2116: 3663-3669, 2010.
22. Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, Marcello J, Herndon JE 2nd, McLendon RE, Janney D, Friedman AH, Bigner DD and Friedman HS: Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 101: 57-66, 2011.
23. Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR and Wen PY: Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol 14: 1511-1518, 2012.
24. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM and Lassman AB: Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73: 1200-1206, 2009.
25. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S and Wen PY: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70: 779-787, 2008.
26. Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, Schultz L and Mikkelsen T: Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91: 329-336, 2009.
27. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M and Cloughesy T: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733-4740, 2009.
28. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS and Fine HA: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27: 740-745, 2009.
29. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
30. U.S. National Institute of Health. National Cancer Institute CTEP CTCAE v3.0. 2011. Available at http://ctep.cancer.gov/reporting/ctc.html
31. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA and Yung WK: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17: 2572-2578, 1999.
32. Fleming TR: One-sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143-151, 1982.
33. Pasquier E, Kavallaris M and Andre N: Metronomic chemotherapy: New rationale for new directions. Nature Rev Clin Oncol 7: 455-465, 2010.
34. Kerbel RS and Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nature Rev Cancer 4: 423-436, 2004.
35. Drevs J, Fakler J, Eisele S, Medinger M, Bing G, Esser N, Marme D and Unger C: Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 24: 1759-1763, 2004.
36. Kerbel R and Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739, 2002.
37. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de BF, Viale G and Goldhirsch A: Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13: 73-80, 2002.
38. Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH and Rustin GJ: Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58: 4363-4367, 1998.
39. Pluderi M, Lucini V, Caronzolo D, Pannacci M, Costa F, Carrabba G, Giussani C, Grosso S, Colleoni F, Scaglione F, Villani R, Bikfalvi A and Bello L: Long-term inhibition of glioma growth by systemic administration of human PEX. J Neurosurg Sci 47: 69-78, 2003.
40. Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O'Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J, Laforme A, Black PM, Folkman J, Kieran M and Wen PY: Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro-Oncology 9: 354-363, 2007.
41. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134, 2007.
42. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM and Figlin RA: Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 356: 115-124, 2007.
43. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 359-378, 2008.
44. Chamberlain MC and Johnston SK: Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol 96: 259-269, 2010.
45. Zustovich F, Lombardi G, Pastorelli D, Farina P, Furini L, Manara R, Dalla Palma M, Rotilio A, Nicoletto O and Zagonel V: Bevacizumab and glioblastomas, single centre experience: how disease history and characteristics may affect clinical outcome. Anticancer Res 30: 5213-5216, 2010.